Press Releases Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Market Closed - Japan Exchange Other stock markets 11:30:00 02/05/2024 am IST			5-day change	1st Jan Change
2,306 ^JPY	-0.80%		+0.65%	-8.37%

30/04	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	RE
29/04	US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ono Pharmaceutical : Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals	30/04	PU
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono	26/04	AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area	25/04	PU
Ono Pharmaceutical : Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers	05/04	PU
Ono Pharmaceutical : Announces Completion of Cancellation of Treasury Stock	29/03	PU
Ono Announces General Sponsorship for the 'Theme Weeks' as Bronze Partner, at the Expo 2025 Osaka, Kansai, Japan	28/03	AQ
Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	25/03	AQ
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	25/03	AQ
Ono Pharmaceutical : Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford	22/03	PU
Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders	15/03	AQ
Ono Pharmaceutical : Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders	14/03	PU
Ono Pharmaceutical : U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	12/03	PU
Ono Pharmaceutical : Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101	06/03	PU
Ono Pharmaceutical Announces Status of Acquisition of Own Shares	04/03	AQ
Ono Pharmaceutical : Announces Status and Completion of Acquisition of Own Shares	04/03	PU
Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets	20/02	AQ
ONO Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49	15/02	AQ
Bristol Myers Squibb - Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits after Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma	23/01	AQ
Ono Pharmaceutical Co., Ltd. - Notice of Changes in Representative Directors	12/01	AQ
Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV's AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs	20/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ono Pharmaceutical Co., Ltd.

Equities

4528

JP3197600004

Press Releases

Filters